Year-in-Review: EmVenio in 2025

This year marks the most transformative chapter in EmVenio’s history! From our rebrand to clinical trial facilitation to the conference circuit, we covered a lot of ground this year. Here are some of the highlights of 2025.

The things we did.

Our rebrand was a major accomplishment in 2025. Earlier this year, PCM Trials, EmVenio Research and Clinical Trial Service made the decision to align services under one brand, leading to the creation of who we are now: EmVenio Clinical Research. While our commitment to our mission and clients remains the same, our visual identity has undergone a refresh. From the colors to a new logo, our new look and feel are authentically us – bright, warm, welcoming and, most importantly, people-centered.

We also launched Patient Navigator, a new service designed to eliminate logistical and financial barriers to clinical trial participation. Our services include arranging transportation for patients and caregivers, securing lodging for patients for the duration of their study participation and assisting with financial reimbursement for eligible expenses. This is our way of rounding out the clinical trial experience, making it truly accessible to all patients of all backgrounds and life experiences.

The research we supported.

This year, we supported more than 140 clinical trials for sponsors and CROs. Among the highlights are two of our principal investigators leading research at EmVenio’s dedicated sites:

• Dr. Renee Dwaihy, M.D., based at our Garden City, Michigan research center, brings over a decade of experience in metabolic and obesity-related studies.
• Dr. Deon Miller, D.O., located at our Riverdale, Georgia research center, is a board-certified emergency medicine physician with more than 10 years of clinical experience and six years as a principal investigator. She has led over 40 trials across diverse therapeutic areas, including obesity and metabolic health.

Additionally, we expanded our PI team in 2025, adding new therapeutic areas such as adult and adolescent psychology and pain management. Collectively, our Principal investigators average 14 years+ of clinical trial experience, and their combined expertise spans more than 100 therapeutic areas.

The places we went.

Our team was out and about this year, and our conferences took us across the United States and Europe. In total, we attended 26 conferences in three countries and seven states. We had a presence at conferences big and small, including DPHARM, SCRS US, SCRS EU, OCT SoCal, OCT New England, SCOPE EU, Clinical Trials in Rural & Triable Communities Pathways Symposium, CNS and DTRA – just to name a few. During our time on the circuit, our team participated in 12 speaker sessions, three speaker panels and hosted five networking receptions.

Additionally, we were honored to be named Best Clinical Research Company at this year’s Vaccine Industry Excellence Awards during the World Vaccine Congress. Every day, we work to make clinical trials more accessible and inclusive to create a more accurate reflection of real-world populations impacted by trial outcomes. This award was an especially meaningful recognition of years of hard work and dedication.

See you in 2026!

We covered a lot of ground in 2025, and we’re looking forward to continuing that upward trajectory in 2026. As we continue to build out our plans for the new year, we’ll update them on the website. Whether we’ve met before or this is your first time hearing of us, we’d love to connect and discuss how we can support your next clinical trial. Contact us today or schedule a meeting to get started.